COVID-19 updates - Get the latest information about Coronavirus and Iowa Heart Center

Emperor HF

Purpose of Study

Investigate the clinical efficacy and safety of the study drug, empagliflozin, in treating subjects who hava a type of chronic heart failure that includes preserved ejection fraction.

Trial Status

In follow up

Eligibility Criteria

18 years or older, chronic heart failure with LVEF > 40%, elevated NT-proBNP, NYHA Class II-IV

Duration of Participation

Approximately 38 months

Contact Name: Ketra Smith

Contact Phone: 515-633-3842

Contact Email: ktsmith@iowaheart.com